TITLE

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

AUTHOR(S)
O L Lopez
PUB. DATE
June 2009
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Jun2009, Vol. 80 Issue 6, p600
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: Patients using cholinesterase inhibitors (ChEIs) have a delay in nursing home (NH) admission compared with those who were not using the medication. There are no long-term studies of the effects of memantine in combination with ChEIs use in Alzheimer disease (AD). This study was conducted to examine the effects of ChEIs and memantine on time to death and time to NH admission. METHODS: Time to NH admission and death was examined in 943 probable AD patients who had at least a 1-year follow-up evaluation. Of these patients, 140 (14.9%) used both ChEIs and memantine, 387 (45.0%) used only ChEIs, and 416 (40.1%) used neither. The mean (SD) follow-up time was 62.3 (35.8) months. The analysis was conducted with multivariable Cox proportional hazard models controlling for critical covariates (ie, age, education level, gender, severity of the dementia, hypertension, diabetes mellitus, heart disease, psychiatric symptoms and use of psychotropic medications). RESULTS: Compared with those who never used cognitive enhancers, patients who used ChEIs had a significant delay in NH admission (HR: 0.37, 95% CI 0.27 to 0.49); this effect was significantly augmented with the addition of memantine (HR: 0.29, 95% CI 0.11 to 0.72) (memantine+ChEI vs ChEI alone). ChEIs alone, or in combination with memantine had no significant association on time to death. CONCLUSIONS: This observational study revealed that the addition of the NMDA receptor antagonist memantine to the treatment of AD with ChEI significantly altered the treated history of AD by extending time to nursing home admission.
ACCESSION #
39989887

 

Related Articles

  • Piracetam, Rivastigmine and Their Joint Consumption Effects on MMSE Score Status in Patients with Alzheimer's Disease. IRANMANESH, FARAD; VAKILIAN, ALIREZA; GADARI, FARANAK; SYADI, AHMADREZA; MEHRABIAN, MILAD; MORADI, MARYAM; RAESY, ELAHE // Iranian Journal of Pharmacology & Therapeutics;Dec2012, Vol. 11 Issue 2, p60 

    Alzheimer's disease is considered the most common cause of dementia. At present, no definite cure is available for healing the disorders and stopping the disease progress. The aim of this study is to study the effects of piracetam, rivastigmine and their joint consumption on MMSE score status in...

  • Acetylcholine and memory-enhancing activity of Ficus racemosa bark. Ahmed, Faiyaz; Chandra, J. N. Narendra Sharath; Manjunath, S. // Pharmacognosy Research;Oct2011, Vol. 3 Issue 4, p246 

    Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder resulting in dementia and enhancement of acetylcholine (Ach) levels in brain using acetylcholinesterase inhibitors is one of the most important approaches for the treatment of AD. Methods: In this study, aqueous...

  • Concurrent use of cholinesterase inhibitors, anticholinergics common.  // PharmacoEconomics & Outcomes News;1/15/2005, Issue 469, p9 

    Discusses the use of acetylcholine receptor antagonists by patients who receive cholinesterase inhibitors for Alzheimer's disease. Percentage of those who received inhibitors that also use the antagonists; Significance of the antagonists to the treatment of Alzheimer's disease; Importance of...

  • Update on the Pharmacological Treatment of Alzheimer's Disease. Massoud, Fadi; Gauthier, Serge // Current Neuropharmacology;Mar2010, Vol. 8 Issue 1, p69 

    Alzheimer's disease (AD) is the most common neurodegenerative disorder. Worldwide prevalence of the disease is estimated at more than 24 million cases. With aging of populations, this number will likely increase to more than 80 million cases by the year 2040. The annual incidence worldwide is...

  • Behandlungs- und Versorgungsstrategien bei Alzheimer und verwandten Demenzen. Förstl, H. // Der Nervenarzt;May2008, Vol. 79 Issue 5, p617 

    The majority of elderly demented patients suffers from mixed dementia, with Alzheimer's-type brain changes being the leading cause of cognitive impairment. Cholinesterase inhibitors and memantin improve cognitive performance in dementia, with a symptomatic parallel shift of 8 to 12 months....

  • Terapijiski koncept Alzheimerove bolesti. Alajbegović, Azra; Alajbegović, Salem // Materia Socio Medica;2007, Vol. 19 Issue 3, p155 

    The use of cholinesterase inhibitors to correct the cholinergic deficit in patients with mild to moderate Alzheimer' disease (AD) is well established.The treatment is only effective in about half of the patients for whom it is prescribed. Vascular dementia may be respond too. Currently the four...

  • Role of cholinesterase inhibitors in dementia care needs rethinking. Pelosi, Anthony J.; McNulty, Seamus V.; Jackson, Graham A. // BMJ: British Medical Journal (International Edition);9/2/2006, Vol. 333 Issue 7566, p491 

    The article looks at the use of cholinesterase inhibitors in dementia care. In 2001 Great Britain's National Institute for Health and Clinical Excellence stated that the National Health Service should make cholinesterase inhibitors, including rivastigmine, galantamine, and donepezil, available...

  • Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease? Giacobini, E. // CNS Drugs;2001, Vol. 15 Issue 2, p85 

    During the last decade, a systematic effort to develop a pharmacological treatment for Alzheimer disease (AD) has resulted in drugs being registered for the first time in the US and Europe for this specific indication. The 3 agents registered are cholinesterase inhibitors (ChEIs). The major...

  • Beyond Tacrine: Recently Developed Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease. Unni, L.K. // CNS Drugs;1998, Vol. 10 Issue 6, p447 

    Alzheimer's disease still remains a diagnosis of exclusion. Until treatment strategies aimed at targeting its underlying aetiology become available, a cholinergic approach appears to be the most promising treatment for improving cognition in this devastating disease. Research to date suggests...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics